Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...

The Trump administration’s new vaccine advisers endorsed this fall's flu vaccines late last week, but only those that don't ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Moderna’s experimental mRNA-based flu vaccine demonstrated a stronger immune response than a currently available standard flu shot in a late-stage phase 3 trial, clearing a path for regulatory ...

It’s a question laid to rest years ago, as studies showed no evidence that the preservative causes any health problems.

Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna ...

Moderna Inc. said Monday its experimental flu shot showed positive results in a late-stage trial. In a Phase 3 study, the ...

The Cambridge biotech believes packaging the two immunizations together will lead to higher uptake of COVID vaccines.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

Moderna said on Monday its experimental influenza vaccine showed superior efficacy compared with a licensed standard-dose ...